VTRSViatris Inc
Pharmaceutical Preparations
- Revenue
- $14.3B
- 3.0% YoY
- Operating margin
- -18.7%
- 27286% YoY
- EBITDA
- $135M
- 95% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 78.8×
- $10.6B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear22% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear19% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $17.8B | $16.2B | $15.4B | $14.7B | $14.3B | 3.0% |
| Operating income | −$34M | $1.6B | $766M | $10M | −$2.7B | 26467% |
| Operating cash flow | $3.0B | $3.0B | $2.9B | $2.3B | $2.3B | 0.6% |
| Capex | $457M | $406M | $377M | $326M | $379M | 16% |
| Stock-based comp | $111M | $116M | $181M | $146M | $178M | 22% |
| Buybacks | $0 | $0 | $250M | $250M | $501M | 100% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.